Unknown EARLY_PHASE1 INTERVENTIONAL 1-arm NCT05686720

Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer

Sponsor: First Affiliated Hospital of Shantou University Medical College

Conditions Advanced Triple Negative Breast Cancer

Updated 4 times since 2023 Last updated: Jan 9, 2023 Started: Feb 1, 2023 Primary completion: Feb 1, 2024 Completion: Jun 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Advanced Triple Negative Breast Cancer, this trial is ongoing. The trial is conducted by First Affiliated Hospital of Shantou University Medical College and has accumulated 4 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Feb 2025 — Present [monthly]

Unknown EARLY_PHASE1

Status: Not Yet Recruiting → Unknown
Sep 2024 — Feb 2025 [monthly]

Not Yet Recruiting EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting EARLY_PHASE1
Feb 2023 — Jul 2024 [monthly]

Not Yet Recruiting EARLY_PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

First Affiliated Hospital of Shantou University Medical College
Guangdong ProCapZoom Biosciences Co., Ltd.

Data source: First Affiliated Hospital of Shantou University Medical College

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shantou, China